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ng liver cirrhosis and/or liver cancer. Occult hepatitis C virus
OCV) infection is characterized by presence of HCV infec-
ion with undetectable hepatitis C antibodies or/and RNA
n serum. Scanty information is available about the etiology
f viral chronic liver diseases in the United Arab Emirates
UAE). Therefore a study was carried out for detecting and
enotyping of HCV & OCV in patients with chronic liver dis-
ase (CLD) in UAE.
Methods: A total of 142 serum samples from CLD patients
nd 139 healthy individuals were tested by polymerase chain
eaction (PCR) & (RT-PCR) in determining HCv RNA&HBVDNA
n serum samples. ELISA tests were used to detect HCV & HBV
arkers in patient sera. Liver biopsies were taken from CLD
atients for immunohistochemistry((IHC) staining.
Results: The results indicated the prevalence of HCV,
ccult HCV, dual (HBV &HCV) and HBV infections at a
ate of 43.7%, 27.5%, 19.0% and 12.7% in CLD patients
espectively. Were as Healthy subjects were positive for
nti body HCV and HBV-DNA at a rate of 3.6% and 2.2%
espectively (P = 0.001). The most prevalent genotypes and
ubtypes of of HCV infection in CDL patients were genotype 4
28.3%),Where as the prevalence of other genotypes,3a,1a,
nd 3b,1b, 5, 2, 3a & 3b, 2a and 1a & 1b were in the range of
5.3 to 1.3%. IHC results for HCV in biopsy tissues revealed
hat 84.6 (11/13) were positive. Histopathological studies of
iver biopsies revealed that patients with HCV infection were
ore likely to have necroinﬂammatory activity and ﬁbrosis
han patients without HCV infection.
Conclusion: Occult HCV is relatively frequent among
atients with CLD in the UAE. Phylogenetic tree showed that
enotype 4 appears to be the dominant genotype Where as
he prevalence of other genotypes that circulating in UAE
opulation.(1b, 5, 2, 3a & 3b, 2a and 1a &1b) were less
ominant than genotype 4.
oi:10.1016/j.ijid.2010.02.1990
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linical features of acute viral hepatitis A complicated
ith acute renal failure
. Choi ∗, B.S. Chin, S.Y. Shin, S.J. Jin, Y.T. Chae, S.H. Han,
.-H. Baek, J.Y. Choi, C.O. Kim, J.M. Kim
Yonsei University College of Medicine, Seoul, Korea, Repub-
ic of
Background: Although acute hepatitis A is usually self-
imited, the clinical manifestations can vary from mild to
evere liver dysfunction. However, little is known about risk
actors and outcome predictors for acute renal failure (ARF)
n acute hepatitis A. The objective of this study was to iden-
ify the simple clinical predictors for acute renal failure
ARF) and its clinical course.
Methods: The study and control groups consisted of
atients who did or did not develop acute renal failure,
espectively, after acute hepatitis A from January 2006 to
une 2009. A total of 396 patients were enrolled in this
tudy. We conducted a retrospective analysis of the inci-
ence, risk factors, and outcomes of patients with acute
epatitis A complicated with ARF.
Results: Thirty patients (7.6%) developed ARF. Older
atients and males were more likely to ARF during hepati-
a
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is A. ARF patients were more likely obese, heavy alcoholics
nd having fulminant course. The ARF patients had a higher
hite blood cell count, higher levels of AST, ALT, total
ilirubin and CRP, lower levels of albumin, more frequent
oagulopathy, and lower platelet count compared with the
thers. On multivariate analysis, male gender [Odds ratio
OR) 9.616, 95% conﬁdence interval (CI) 1.307—70.000,
= 0.026], the presence of hypertension [OR 5.91, 95%
I 1.407-24.824, P = 0.015] and fulminant hepatitis [OR
7.95, 95% CI 10.399—322.928, P < 0.001] were indepen-
ent risk factors of hepatitis A-associated ARF. Of the 30
atients with ARF, 23 (76.7%) patients fully recovered; 14
46.7%) patients recovered with conservative care only,
nd nine (30%) patients required short-term hemodialysis.
he two groups of spontaneous recovery from ARF (n = 14)
nd hemodialysis/death (n = 16) showed signiﬁcant differ-
nces in platelet count at its worst value, creatinine at
ts worst value, albumin at admission, INR at admission
nd fulminant hepatic failure. Albumin level at admission
igher than 3.6mg/dL [OR 13.183, 95% CI 1.064-163.403,
= 0.045] and INR at admission less than 1.6 [OR 14.969,
5% CI 1.346-166.447, P = 0.028] were independent predic-
ors of spontaneous recovery of ARF during acute hepatitis
.
Conclusion: Acute renal failure associated with acute
epatitis A is not a rare complication. Male gender and
ypertension are risk factors of ARF. Patients complicated
ith ARF, higher albumin level and shorter INR at admission
ould a favorable prognostic factor.
oi:10.1016/j.ijid.2010.02.1991
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Arak University of Medical Sciences, Arak, Iran, (Islamic
epublic of)
Islamic Azad University of Arak Branch, Arak, Iran, (Islamic
epublic of)
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Pasteur Institute of Iran, Tehran, Iran, (Islamic Republic
f)
Arak medica university, Arak, Iran, (Islamic Republic of)
Arak University of Medical science, Arak, Iran, (Islamic
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Tehran, Iran, (Islamic Republic of)
Background: Prevalence of hepatitis B virus (HBV), hep-
titis C virus (HCV) and co-infection of HBV and HCV are high
mong injection drug users. Hepatitis B may be presented
nly with isolated Hepatitis B core antibody (anti-HBc). This
tudy aimed to determine the prevalence of isolated anti-
Bc among injection drug users in central province of Iran
nd comparison of its prevalence with healthy blood donors.
Methods: A total of 531 voluntary blood donors with mean
ge of 36± 10.18 years (range 16—60 years) and 153 injec-
ion drug users with mean age of 30.66± 5.92 years (range
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20—50 years) were enrolled in this study. All of the injec-
tion drug users were prisoners. Hepatitis B surface antigen
(HBsAg), hepatitis B surface antibody (anti-HBs), anti-HBc,
Anti-HIV and hepatitis C antibody (anti-HCV) were tested in
all subjects.
Results: Of the 531 blood donors, 11 subjects (2.1%) had
isolated anti-HBc and of 153 injection drug users, 12 cases
(7.84%) showed isolated anti-HBc. All of 12 injection drug
users with isolated anti-HBc were also HCV positive. Sero-
logic proﬁle of 2 groups was shown in Table 1.
Variable Blood donors Injection drug users P value
HBsAg 0.4% 7.2% 0
Anti-HBs 31.8% 43.8% 0
Anti-HBc 11.5% 35% 0
Anti-HCV 0.2% 59.5% 0
Anti-HIV 0% 5.9% 0
Conclusion: Our study showed that prevalence of isolated
anti-HBc among injection drug users was 3.73 fold in com-
parison with blood donors. This study supports that injection
drug use and incarceration is contributing to increase preva-
lence of isolated anti-HBc.
doi:10.1016/j.ijid.2010.02.1992
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Persistence of protective antibodies against Hepatitis B
virus among vaccinated health workers, Al-Hussein Hos-
pital, Salt, Jordan, 2008
S. Sheikh Ali 1,∗, M. Jaghbir2
1 MOH, Amman, Jordan
2 Dean Faculty of Medicine, Hashemite University, Zarka Jor-
dan, Amman, Jordan
Background: Health workers (HWs) have occupational
exposure to blood or body ﬂuids; unvaccinated HWs or those
vaccinated with low hepatitis-B surface antibodies‘‘(anti-
HBs) <10UI’’ are at higher risk of Hepatitis-B infection they
could be focus for dissemination of infection. Duration of
protection after fully vaccination is not known. The objec-
tive is to assess the immunogenicity ‘‘anti-HBs ‘‘10mIU/ml’’
post vaccination among HWs.
Methods: Two stage study; cross-sectional and follow-up
prospective-cohort. Voluntary HWs who met the inclusion
criteria were surveyed and tested primary for hepatitis-B
core antibodies and hepatitis-B surface antigen, only those
with negative results were tested for ‘‘anti-HBs’’; fully vac-
cinated HWs with negative anti-HBs were voluntary enrolled
in the second stage,retested for anti-HBs after 45 days from
a booster dose.
Results: 252 HWs participate in the study; 10% of those
don’t meet the inclusion criteria, primary study sample was
226 HWs, 81% were fully and 19% were partially vaccinated.
There was a signiﬁcant association between the number of
vaccine doses and the presence of anti-HBs, p-value-0.0002.
There is a signiﬁcant difference regarding the presence of
anti-HBs among fully or partially vaccinated HWs; P-value-
0.003. To verify ‘‘persistence’’, statistics were limited to
182 fully vaccinated HWs; was found signiﬁcant associa-
tion between the time period from the last administrated
doses, age at vaccination, duration of practice and the per-
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istence of antibodies, P-value-0.00004, 0.040, and 0.010
espectively. There were no signiﬁcant differences regard-
ng the vaccination site, Fisher exact: 0.7018. There is no
ssociation between the ‘‘place of working, profession, and
requency of exposure to blood or needle stick injury’’ and
he persistence of antibodies. 8% of participants in second
tage didn’t response by reforming the anti-HBs. 65% of
Ws who were exposed to a needle stick injury report no
ost exposure preventive measures was taken after they had
eported the injury.
Conclusion: The Hepatitis-B prevalence among HWs was
0%; the non-response rate to vaccine was 8%; the prob-
bility for antibodies-persistence is declining by time;
robability of antibodies persistence is highly signiﬁcant if
he period from the last administrated dose is less than three
ears and increases with a booster dose. The older age the
accine was administrated the higher was the risk to non
esponse to vaccine.
oi:10.1016/j.ijid.2010.02.1993
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egional and ethnical aspects of viral hepatitis B in preg-
ant women in Slovakia
. Kristian, I. Schreter, Z. Paralicova, P. Jarcuska ∗, L.
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Faculty of Medicine, University of P.J.Safarik, Kosice, Slo-
akia
Background: The estimated prevalence of HBsAg in Slo-
ak population is <2% with supposed regional differences
nd higher prevalence of HBV infection in Roma popula-
ion. Pregnant women constitute a special subgroup, that
s subject to routine HBsAg screening because of the risk
f vertical transmission, and also pregnancy can modify the
ourse of hepatitis B infection. The aim of this study was
o determine the prevalence of HBV infection in pregnant
omen in districts of eastern Slovakia with diverse preva-
ence of Roma population and to determine the subset of
omen with chronic hepatitis B and increased risk of vertical
ransmission.
Methods: We have analyzed data from 9 regional Depart-
ents of Clinical Microbiology from January 2008 till June
009. We have evaluated the portion of HBsAg positive ﬁnd-
ngs from the overall examined samples and among pregnant
omen. Available sera from HBsAg positive pregnant women
ere also screened for ALT, HBeAg and HBV DNA.
Results: Overall, 44,912 sera samples were examined,
ith 10,739 from pregnancy screening. The number of HBsAg
ositive samples overall and during pregnancy was 803
1.79%) and 251 (2.34%) respectively. Comparing districts
ith higher (>4%) and lower (<3%) prevalence of Roma popu-
ation, there was no notable difference in the overall HBsAg
revalence (1.85% vs. 1.68%), however in the subgroup of
regnant women (2.69% vs. 1.25%) this difference was highly
igniﬁcant (p < 0.001). HBV DNA was evaluated in 158 preg-
ant women, 19 patients had viral load >105 copies/ml, 27
n the range of 104-105 copies/ml and 112 patients < 104
r negative. HBeAg positivity was conﬁrmed in 17 of 146
xamined samples (11.6%) and elevated ALT in 11 of 69 cases
15.9%). Twelve out of 58 patients with normal ALT (21%) had
